| Name | Title | Contact Details |
|---|
Headquartered in Los Angeles, California, Manufacturers Bank is a wholly owned subsidiary of SMBC Americas Holding, Inc., a member of SMBC Group. For over 60 years, the Commercial Bank division of Manufacturers Bank has been serving middle-market and corporate businesses by providing sophisticated solutions and expertise with the personal touch of a community bank. The Commercial Bank division serves the specialized needs of middle-market and corporate businesses, franchise finance including quick service restaurants, manufacturers, wholesalers, distributors, importers, exporters, and service companies. We offer a comprehensive suite of credit, deposit and treasury management solutions including foreign exchange and trade finance. The Commercial Bank has offices in Los Angeles, Beverly Hills, Brea, Encino, Glendale, Newport Beach, San Jose, and Torrance. Member FDIC
The globally operating Geberit Group is a European leader in the field of sanitary products. Geberit operates as an integrated group with a very strong local presence in many countries, providing unique added value in sanitary technology and bathroom ceramics. The Group is headquartered in Rapperswil-Jona, Switzerland, with a production network encompassing more than 30 production facilities. In North America, Geberit provides concealed systems for wall-hung toilets and fixtures. Geberit systems improve the look of any bathroom by hiding unsightly plumbing hardware. Replacing a standard toilet with the Geberit system results in more usable space, improved hygiene, and better accessibility. The unique dual-flush valve saves water and is practically maintenance-free. Geberit also offers cable-controlled bath waste and overflows in a variety of designer finishes. Critical working parts are outside the waterway, ensuring years of trouble-free operation. With more than 12,000 employees in over 40 countries, Geberit generates net sales of CHF 2.6 billion. The Geberit shares are listed on the SIX Swiss Exchange; since 2012, the Geberit share has been included in the SMI (Swiss Market Index).
Franklin Products, inc. was founded in 1992 to fill a niche in the marketplace for high quality fluid bed dryer exhaust filters at highly competitive price points for the pharmaceutical industry. Successes in the pharmaceutical industry led to rapid growth into other industries such as food production and chemical manufacturing. All markets where the best quality product is required to do the job!
Biesse Group is a global leader in the design, manufacture, and distribution of machinery, integrated systems, components, and software for processing various materials, including wood, glass, stone, plastic, and metal. Founded in 1969 in Pesaro, Italy, the company has grown into a multinational enterprise with around 4,400 employees and a presence in 12 industrial sites and 39 subsidiaries worldwide. Biesse is listed on the STAR segment of the Italian Stock Exchange and exports 90% of its production. The company offers a wide range of solutions, including CNC machining centers, drilling machines, and automated systems tailored for different materials. Biesse emphasizes innovation and sustainability, investing €14 million annually in research and development and holding over 200-250 patents. Its advanced technologies incorporate AI and IoT, supporting industries such as furniture, construction, automotive, aerospace, and shipbuilding. Biesse also provides training and demonstrations through its global network of showrooms and campuses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.